Home › Funds › Patient Capital Management, LLC › RPRX

Patient Capital Management, LLC position in RPRX

ROYALTY PHARMA PLC · Health Care

Patient Capital Management, LLC reported holding 3,422,067 shares of RPRX (ROYALTY PHARMA PLC) in its Q3 2026 13F filing — a position valued at US$199.7M, representing 6.75% of its reported portfolio and ranking #1 among its reported holdings. Patient Capital Management, LLC has disclosed RPRX holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

Latest position (Q3 2026)3.42M sh
Reported value held$199.71M
Portfolio Weight6.75%
First reportedQ4 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Patient Capital Management, LLC's RPRX position evolved

Patient Capital Management, LLC first disclosed a stake in RPRX in Q4 2023 at 1,254,780 shares (US$35.2M). The position peaked in Q2 2026 at 3,598,808 shares, worth US$201.8M. Across 12 filings, Patient Capital Management, LLC increased the stake 8 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 3,422,067 shares valued at US$199.7M — a reduction of -176,741 shares quarter over quarter.. Notable position changes include a 43% increase in Q3 2024 (shares fell 10% over the following quarter), a 41% increase in Q4 2024 (shares rose 22% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 1.25M $35.25M New
Q1 2024 1.42M $43.12M Add
Q2 2024 1.42M $37.56M Hold
Q3 2024 2.04M $57.75M Add
Q4 2024 2.88M $73.34M Add
Q1 2025 2.97M $92.54M Add
Q2 2025 2.99M $107.66M Add
Q3 2025 3.12M $110.00M Add
Q4 2025 3.33M $128.81M Add
Q1 2026 3.64M $174.79M Add
Q2 2026 3.60M $201.79M Reduce
Q3 2026 3.42M $199.71M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RPRX and 13F data

RPRX (ROYALTY PHARMA PLC) is a Health Care company. 47 other funds we track also report a position in RPRX — the largest reported positions include Swedbank AB (US$598.8M), Baillie Gifford & Co (US$534.1M), ROYAL LONDON ASSET MANAGEMENT LTD (US$348.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RPRX

All RPRX fund holders →

FAQ

How long has Patient Capital Management, LLC held RPRX?

Patient Capital Management, LLC has disclosed RPRX holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

What is Patient Capital Management, LLC's current position in RPRX?

As of Q3 2026, Patient Capital Management, LLC holds 3.42M shares of RPRX (ROYALTY PHARMA PLC), valued at $199.71M, representing 6.75% of its reported portfolio and ranking #1.

Has Patient Capital Management, LLC been buying or selling RPRX?

In the latest 13F filing (Q3 2026), Patient Capital Management, LLC reduced its position in RPRX. The position peaked in Q2 2026 at 3.60M shares.

Which other funds hold RPRX?

Other major institutional holders of RPRX include Swedbank AB, Baillie Gifford & Co, ROYAL LONDON ASSET MANAGEMENT LTD, among 47 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.